Liao Wenli, Lin Jie, Jia Huaiyu, Zhou Cui, Zhang Ying, Lin Yishuai, Ye Jianzhong, Cao Jianming, Zhou Tieli
Department of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, People's Republic of China.
Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Infect Drug Resist. 2020 Oct 9;13:3551-3561. doi: 10.2147/IDR.S273784. eCollection 2020.
Colistin is being administered as last-line therapy for patients that have failed to respond to other available antibiotics that are active against . The underlying mechanisms of colistin resistance and heteroresistance remain largely uncharacterized. The present study investigated the mechanisms of resistance and heteroresistance to colistin in isolates from Wenzhou, China.
Colistin resistance was detected by the broth microdilution method (BMD). Colistin heteroresistance was determined by population analysis profiles (PAPs). The polymerase chain reaction (PCR) was conducted to detect and and quantitative real-time PCR (qRT-PCR) was used to determine the expression levels of and . Lipid A characterization was conducted by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS).
0.69% (2/291) of strains were resistant to colistin, whereas the heteroresistance rate reached 1.37% (4/291). , the mobile colistin-resistance gene, was present in the two resistant isolates. The substitutions in PmrB were detected in the two heteroresistant isolates. The transcripts levels of the operon were upregulated in two of the heteroresistant isolates. carbonylcyanide m-chlorophenylhydrazone (CCCP) was able to reverse colistin resistance of all isolates tested and exhibited a significantly higher effect on colistin-heteroresistant isolates. MALDI-TOF MS indicated that the additional phosphoethanolamine (PEtn) moieties in lipid A profiles were present both in colistin-resistant and heteroresistant isolates.
The present study was the first to investigate the differential mechanisms between colistin resistance and heteroresistance. The development of colistin heteroresistance should be addressed in future clinical surveillance.
对于对其他有效抗生素无反应的患者,多粘菌素作为最后一线治疗药物使用。多粘菌素耐药和异质性耐药的潜在机制在很大程度上仍未明确。本研究调查了来自中国温州的分离株对多粘菌素的耐药和异质性耐药机制。
采用肉汤微量稀释法(BMD)检测多粘菌素耐药性。通过群体分析谱(PAPs)确定多粘菌素异质性耐药。进行聚合酶链反应(PCR)检测 和 ,并使用定量实时PCR(qRT-PCR)测定 和 的表达水平。通过基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF MS)进行脂多糖A表征。
0.69%(2/291)的 菌株对多粘菌素耐药,而异质性耐药率达到1.37%(4/291)。移动性多粘菌素耐药基因 存在于两个耐药分离株中。在两个异质性耐药分离株中检测到PmrB的替换。在两个异质性耐药分离株中, 操纵子的转录水平上调。羰基氰化物间氯苯腙(CCCP)能够逆转所有测试分离株的多粘菌素耐药性,并且对多粘菌素异质性耐药分离株表现出显著更高的效果。MALDI-TOF MS表明,脂多糖A谱中额外的磷酸乙醇胺(PEtn)部分在多粘菌素耐药和异质性耐药分离株中均存在。
本研究首次调查了多粘菌素耐药和异质性耐药之间的差异机制。未来临床监测中应关注多粘菌素异质性耐药的发展。